Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (387)	7/16/1998 8:09:00 PM
From: ok	Respond to of 1025

The Cabot market letter picked Igen as the stock of the month,with a buy recommendation. Oscar

To: John Zwiener who wrote (387)	7/22/1998 6:25:00 PM
From: James Perry	Read Replies (1) \| Respond to of 1025

Gee, John, I am on the road in my RV, and will be so for about three more weeks. But I have just managed to get to the keyboard of a computer and saw your note re tests. You mentioned a couple about which I had seen nothing - the e-Coli (which would seem to me to be damned important), and another of which I have no knowledge, as well as the license for the heart problem (CHF)market. Now, I saw a press release on that last one, and also a press release documenting that all of the considerable number of inside trades had been buys. I didn't recognize the specific heart test, and assumed that it is a new test which will have to become medically accepted. I assume that it will be accepted, and I was much impressed that a foreign company that had developed the test would seek out Igen (or accept Igen) as the exclusive agent to handle its test. Speaks very well for Igen. One would suspect that other marker developers will likewise license their use to Igen. Like you, I hope that Roche doesn't harm this goose which lays such golden eggs!